Insulin delivery devices have evolved in a big way from conventional metal syringes to intelligent insulin pens and implantable Continuous Glucose Monitoring (CGM) system for glycemic control in people with diabetes. In the year 2018, FDA approved Senseonics' Eversense continuous glucose monitoring (CGM) system, the first implantable CGM in the United States.
The report ?Global Insulin Delivery Device Market - (By Type-Vials & Syringes, Insulin Pens & Insulin Pumps; By Region- North America, Europe & Asia Pacific) Market Outlook 2024? provides an in-depth analysis of global insulin as well as insulin delivery devices market across segments such as Vials & Syringes, Insulin Pens & Insulin Pumps. Market outlook for insulin delivery devices market overall as well as across various sub-segments has been provided for the period 2018-24. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global insulin delivery devices market. The report has been segmented as following:-
Market Segments
? Vials & Syringes
? Insulin Pens
? Insulin Pumps
Geographical Coverage
? North America - The US
? Europe
? Asia Pacific
Key Vendors
? Novo Nordisk
? Sanofi Aventis
? Eli Lilly and Company
? Merck & Co.

Insulin is a peptide hormone produced by pancreas and is central to regulating carbohydrate and fat metabolism in the body. Insulin therapy is used for treatment of people with type 1 diabetes in order to avoid complications arising from hyperglycemia. Insulin is administered mainly through subcutaneous insulin injections such as vials and syringes, insulin pens, and insulin pumps. In addition to this, various other physiological minimally invasive or noninvasive ways for delivering insulin are oral, buccal, nasal, peritoneal and transdermal.
Global insulin market has witnessed strong growth owing various underlying favorable dynamics. Growth of the market is propelled by increasing incidences of diabetes, rise in geriatric population, growing obese population, propagation of Diabetes management awareness and government impetus. However, the market faces several challenges such as high cost of insulin pumps, insurance coverage issues, regulatory pressure and technological issues.
The report ?Global Insulin Delivery Device Market - (By Type-Vials & Syringes, Insulin Pens & Insulin Pumps; By Region- North America, Europe & Asia Pacific) Market Outlook 2024? provides in-depth analysis of the current scenario, detailed market outlook of the global insulin delivery devices market with coverage on major market segments such as Vials & Syringes, Insulin Pens & Insulin Pumps. Future forecasts of insulin delivery devices market overall and across various sub-segments till 2024 is provided in the report. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global insulin delivery devices market include Novo Nordisk, Sanofi Aventis, Eli Lilly and Company, Merck & Co., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global insulin delivery devices market.